AIMS: The primary aims of the Korean Hereditary Breast Cancer (KOHBRA) study are to estimate the prevalence of BRCA1/2 mutations and ovarian cancer among a high-risk group of patients with hereditary breast cancer and their families. MATERIALS AND METHODS: The KOHBRA study is a prospective multicentre cohort identifying cases and their families. Between May 2007 and May 2010, the KOHBRA study enrolled up to 2000 subjects. All participants received genetic counselling and BRCA genetic testing; the clinical information and blood samples for blood banking were collected. An interim analysis of the prevalence of BRCA1/2 mutations and ovarian cancer in Korean subjects was determined from the initial 975 patients who presented to 33 centres. RESULTS: By April 2009, a total of 167 mutation carriers among 853 probands were identified. The prevalence of the BRCA mutation was as follows: 24.8% (106/428) for breast cancer patients with a family history of breast/ovarian cancers; 11.3% (24/212) for patients with early-onset (<35 years) breast cancer without a family history; 22.1% (15/68) for patients with bilateral breast cancer; male breast cancer in 8.3% (1/12); and 33.4% (1/3) for patients with breast and ovarian cancer. CONCLUSIONS: The results of this study suggest that the prevalence of BRCA mutations in Korean subjects is similar to the prevalence reported among Western cohorts. However, weak family history and non-familial early-onset of breast cancer were significant factors associated with carrying the BRCA mutation in Korean breast cancer patients. Completion of the KOHBRA study is needed to confirm these findings.
AIMS: The primary aims of the Korean Hereditary Breast Cancer (KOHBRA) study are to estimate the prevalence of BRCA1/2 mutations and ovarian cancer among a high-risk group of patients with hereditary breast cancer and their families. MATERIALS AND METHODS: The KOHBRA study is a prospective multicentre cohort identifying cases and their families. Between May 2007 and May 2010, the KOHBRA study enrolled up to 2000 subjects. All participants received genetic counselling and BRCA genetic testing; the clinical information and blood samples for blood banking were collected. An interim analysis of the prevalence of BRCA1/2 mutations and ovarian cancer in Korean subjects was determined from the initial 975 patients who presented to 33 centres. RESULTS: By April 2009, a total of 167 mutation carriers among 853 probands were identified. The prevalence of the BRCA mutation was as follows: 24.8% (106/428) for breast cancerpatients with a family history of breast/ovarian cancers; 11.3% (24/212) for patients with early-onset (<35 years) breast cancer without a family history; 22.1% (15/68) for patients with bilateral breast cancer; male breast cancer in 8.3% (1/12); and 33.4% (1/3) for patients with breast and ovarian cancer. CONCLUSIONS: The results of this study suggest that the prevalence of BRCA mutations in Korean subjects is similar to the prevalence reported among Western cohorts. However, weak family history and non-familial early-onset of breast cancer were significant factors associated with carrying the BRCA mutation in Korean breast cancerpatients. Completion of the KOHBRA study is needed to confirm these findings.
Authors: Ja Young Cho; Dae-Yeon Cho; Sei Hyun Ahn; Su-Youn Choi; Inkyung Shin; Hyun Gyu Park; Jong Won Lee; Hee Jeong Kim; Jong Han Yu; Beom Seok Ko; Bo Kyung Ku; Byung Ho Son Journal: Fam Cancer Date: 2014-06 Impact factor: 2.375
Authors: Ava Kwong; Vivian Y Shin; John C W Ho; Eunyoung Kang; Seigo Nakamura; Soo-Hwang Teo; Ann S G Lee; Jen-Hwei Sng; Ophira M Ginsburg; Allison W Kurian; Jeffrey N Weitzel; Man-Ting Siu; Fian B F Law; Tsun-Leung Chan; Steven A Narod; James M Ford; Edmond S K Ma; Sung-Won Kim Journal: J Med Genet Date: 2015-07-17 Impact factor: 6.318
Authors: Sungmin Park; Jeong Eon Lee; Jai Min Ryu; Issac Kim; Soo Youn Bae; Se Kyung Lee; Jonghan Yu; Seok Won Kim; Seok Jin Nam Journal: World J Surg Date: 2018-05 Impact factor: 3.352
Authors: Haeyoung Kim; Dae-Yeon Cho; Doo Ho Choi; Gee Hue Jung; Inkyung Shin; Won Park; Seung Jae Huh; Sung-Won Kim; Sue K Park; Jong Won Lee; Seok Jin Nam; Jeong Eon Lee; Won Ho Gil; Seok Won Kim Journal: Fam Cancer Date: 2015-09 Impact factor: 2.375
Authors: Wei Zheng; Ben Zhang; Qiuyin Cai; Hyuna Sung; Kyriaki Michailidou; Jiajun Shi; Ji-Yeob Choi; Jirong Long; Joe Dennis; Manjeet K Humphreys; Qin Wang; Wei Lu; Yu-Tang Gao; Chun Li; Hui Cai; Sue K Park; Keun-Young Yoo; Dong-Young Noh; Wonshik Han; Alison M Dunning; Javier Benitez; Daniel Vincent; Francois Bacot; Daniel Tessier; Sung-Won Kim; Min Hyuk Lee; Jong Won Lee; Jong-Young Lee; Yong-Bing Xiang; Ying Zheng; Wenjin Wang; Bu-Tian Ji; Keitaro Matsuo; Hidemi Ito; Hiroji Iwata; Hideo Tanaka; Anna H Wu; Chiu-chen Tseng; David Van Den Berg; Daniel O Stram; Soo Hwang Teo; Cheng Har Yip; In Nee Kang; Tien Y Wong; Chen-Yang Shen; Jyh-Cherng Yu; Chiun-Sheng Huang; Ming-Feng Hou; Mikael Hartman; Hui Miao; Soo Chin Lee; Thomas Choudary Putti; Kenneth Muir; Artitaya Lophatananon; Sarah Stewart-Brown; Pornthep Siriwanarangsan; Suleeporn Sangrajrang; Hongbing Shen; Kexin Chen; Pei-Ei Wu; Zefang Ren; Christopher A Haiman; Aiko Sueta; Mi Kyung Kim; Ui Soon Khoo; Motoki Iwasaki; Paul D P Pharoah; Wanqing Wen; Per Hall; Xiao-Ou Shu; Douglas F Easton; Daehee Kang Journal: Hum Mol Genet Date: 2013-03-27 Impact factor: 6.150